Education
About Us
Working with TipRanks
Follow Us
Black Diamond Therapeutics (BDTX)
NASDAQ:BDTX
BDTX Analyst Ratings
Strong Buy
5 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
BDTX Stock 12 Month Forecast
Average Price Target
$8.25
▲(223.53% Upside)
| Highest Price Target$10.00 | Average Price Target$8.25 | Lowest Price Target$6.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Piper Sandler
$9
Buy
252.94%
Upside
Reiterated
12/04/25
Guggenheim
―
Hold
―
Downgraded
12/03/25
H.C. Wainwright
$10
Buy
292.16%
Upside
Reiterated
12/03/25
Promising Potential of Silevertinib in EGFR-Mutant NSCLC: Buy Rating ReiteratedValuation and Risks. We employ a discounted cash flow (DCF)-based valuation methodology, which assigns a 15% probability of launch to BDTX-1535 in EGFR+ NSCLC. We apply a 12% discount rate, 29% effective tax rate, and 1.5% terminal growth rate. These assumptions yield a total firm value of ~$597M, which translates into a price objective of $10 per share, assuming 57.1M shares outstanding.
Stifel Nicolaus
$8
Buy
213.73%
Upside
Reiterated
12/03/25
TD Cowen
―
Buy
―
Reiterated
11/06/25
Freedom Capital Markets
$6
Buy
135.29%
Upside
Initiated
09/30/25
Raymond James
$3.08→$11
Buy
331.37%
Upside
Reiterated
09/10/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Piper Sandler
$9
Buy
252.94%
Upside
Reiterated
12/04/25
Guggenheim
―
Hold
―
Downgraded
12/03/25
H.C. Wainwright
$10
Buy
292.16%
Upside
Reiterated
12/03/25
Promising Potential of Silevertinib in EGFR-Mutant NSCLC: Buy Rating ReiteratedValuation and Risks. We employ a discounted cash flow (DCF)-based valuation methodology, which assigns a 15% probability of launch to BDTX-1535 in EGFR+ NSCLC. We apply a 12% discount rate, 29% effective tax rate, and 1.5% terminal growth rate. These assumptions yield a total firm value of ~$597M, which translates into a price objective of $10 per share, assuming 57.1M shares outstanding.
Stifel Nicolaus
$8
Buy
213.73%
Upside
Reiterated
12/03/25
TD Cowen
―
Buy
―
Reiterated
11/06/25
Freedom Capital Markets
$6
Buy
135.29%
Upside
Initiated
09/30/25
Raymond James
$3.08→$11
Buy
331.37%
Upside
Reiterated
09/10/25
Best Analysts Covering Black Diamond Therapeutics
1 Month
xxx
Success Rate
7/13 ratings generated profit
Average Return
+4.02%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 53.85% of your transactions generating a profit, with an average return of +4.02% per trade.
3 Months
xxx
Success Rate
7/13 ratings generated profit
Average Return
+11.73%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 53.85% of your transactions generating a profit, with an average return of +11.73% per trade.
1 Year
Success Rate
6/13 ratings generated profit
Average Return
-9.08%
reiterated a buy rating 2 months ago
Copying Marc Frahm's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of -9.08% per trade.
2 Years
xxx
Success Rate
5/15 ratings generated profit
Average Return
-11.61%
reiterated a xxx
rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -11.61% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
BDTX Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
2
5
5
7
7
Buy
2
1
1
1
1
Hold
0
0
0
0
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
4
6
6
8
9
Each month's total comprises the sum of three months' worth of ratings.
BDTX Financial Forecast
BDTX Stock Forecast FAQ
What is BDTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Black Diamond Therapeutics’s 12-month average price target is 8.25.
What is BDTX’s upside potential, based on the analysts’ average price target?
Black Diamond Therapeutics has 223.53% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BDTX a Buy, Sell or Hold?
Black Diamond Therapeutics has a consensus rating of Strong Buy which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.
What is Black Diamond Therapeutics’s price target?
The average price target for Black Diamond Therapeutics is 8.25. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $10.00 ,the lowest forecast is $6.00. The average price target represents 223.53% Increase from the current price of $2.55.
The highest analyst price target is $10.00 ,the lowest forecast is $6.00. The average price target represents 223.53% Increase from the current price of $2.55.
What do analysts say about Black Diamond Therapeutics?
Black Diamond Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of BDTX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.